1410 RESULTS
CONFERENCE COVERAGE 2024-11-21 Conference Coverage Yes, blood tests for Alzheimer’s disease are ready for prime time. So pronounced Suzanne Schindler, Washington University, St. Louis, in a keynote presentation at CTAD 2024 last month in Madrid. In answering a question that has been ra
CONFERENCE COVERAGE 2024-11-15 Conference Coverage Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October 29-November 1 in Madrid, speakers upda
CONFERENCE COVERAGE 2024-11-14 Conference Coverage While anti-tau antibodies are beginning to look promising (see previous story), small molecules that modify tau proteins haven’t yet fared well in clinical trials. At the 16th Clinical Trials on Alzheimer’s Disease conference, held Oct
CONFERENCE COVERAGE 2024-11-14 Conference Coverage The fifth time may be the charm for antibodies targeting tau. At the 16th Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 1 in Madrid, Brussels-based UCB Pharma presented the first signal that a monoclona
CONFERENCE COVERAGE 2024-11-14 Conference Coverage Lecanemab has been in clinical use in the U.S. for nearly two years, and in Japan for not quite a year. How is it going? At the Clinical Trials on Alzheimer’s Disease conference, held October 29 through November 1 in Madrid, Spain, spe
CONFERENCE COVERAGE 2024-11-08 Conference Coverage Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease conference, held October 29-Nov
CONFERENCE COVERAGE 2024-11-08 Conference Coverage Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of hazardous brain bleeding, reflected i
CONFERENCE COVERAGE 2024-09-19 Conference Coverage Alzheimer’s is a multifaceted disease, particularly in its sporadic, late-onset form. Myriad factors—genetics, environment, cardiovascular health, metabolism, and inflammation—contribute to a decades-long process. Generating animal mod
CONFERENCE COVERAGE 2024-09-04 Conference Coverage Ever since variants in the gene for TMEM106b were tied to frontotemporal dementia, Alzheimer’s, and other neurodegenerative diseases, this endolysosomal protein has been a head-scratcher for scientists. Its ability to surprise is exemp
CONFERENCE COVERAGE 2024-08-30 Conference Coverage As amyloid immunotherapy is being rolled out, mostly in specialty care thus far, both treating physicians and researchers have many questions about it. Scientists at the Alzheimer’s Association International Conference, held last month
CONFERENCE COVERAGE 2024-08-29 Conference Coverage Now that lecanemab has been in clinical use in the U.S. for a little over a year, doctors are asking how long they should treat. This remains an open question. Drug maker Eisai has proposed to the FDA, in a supplemental biological lice
CONFERENCE COVERAGE 2024-08-28 Conference Coverage The brain shrinkage seen on amyloid immunotherapy remains an unsolved and concerning riddle. At the Alzheimer’s Association International Conference, held July 27 to August 1 in Philadelphia, Nick Fox of University College London offer
CONFERENCE COVERAGE 2024-08-27 Conference Coverage In the brain, location is everything. And the throngs of cells that live there are nothing without the billions of distinct connections between them. Although scientists can use single-cell transcriptomics to survey gene expression in
CONFERENCE COVERAGE 2024-08-23 Conference Coverage A new multiplex diagnostic method appears poised to resculpt the biomarker landscape. NULISA, aka NUcleic acid Linked Immunosorbent Assay, can detect Aβ peptides, p-tau isoforms, and other potential markers of neurodegeneration with se
CONFERENCE COVERAGE 2024-08-23 Conference Coverage Jab a finger, draw up a spot of blood with a test strip, let it dry, then mail it off to your doctor. Could testing for Alzheimer’s disease become that simple? Quite possibly. Modern immunoassays are so sensitive they can detect marker
